Neutrophil-lymphocyte and Platelet-lymphocyte Ratios and Their Relations to Vascular Comlications and Glycemic Control in Patients With Type 2 Diabetes Attending The Diabetes Center of Assiut University Hospitals

NCT06073756 | Not Yet Recruiting

• 1 other identifier: NLR and PLR and in type 2 DM
• Study Type: observational
• Target: 106
• Locations: 0 countries
• Sites: N/A

Brief Summary

Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

Conditions

Vascular Complication, Diabetic

Keywords

Neutrophils to lymhocyte ratio and platelets to lymhocyte ratio

Outcome Measures

Primary Outcomes (1)

• Neutrophil-to-lymphocyte ratio and platelets to lymphocytes ratio

  Measurement of Neutrophils to lymhocyte ratio and platelets to lymhocyte ratio in patients with type 2 DM

  Basline

Secondary Outcomes (1)

• HbA1c with good glycemic control and have HBA1C lower than 7and poor glycemic control and have HBA1C higher than 7with prescence or abscence of vascular complications

  Basline

Study Arms (2)

1

Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C \<7and ages ranging from ≥18 old.

Radiation: Echocardiogram

2

Type 2 diabetes mellitus (T2DM) patients with poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old

Radiation: Echocardiogram

Interventions

Echocardiogram RADIATION

Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

Also known as: ALB / cr ratio, Fundus examination, ECG, Doppler on lower limbs, Nerve conduction, Echo

1; 2

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

You may qualify if:

• Type 2 diabetes mellitus (T2DM) patients with good glycemic control and have HBA1C \<7and ages ranging from ≥18 old. And poor glycemic control and have HBA1C ≥7 and ages rang from ≥ 18 years old

You may not qualify if:

• Patients with, type 1 diabetes mellitus
• Idiopathic thrombocytopenic purpura,
• liver cell failure
• Myeloproliferative neoplasm
• patients on anticoagulant drugs , anti platelet drugs or on steroids were excluded from the study

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Diabetic Angiopathies

Interventions

Albumins; Neural Conduction; Caves

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Proteins; Amino Acids, Peptides, and Proteins; Electrophysiological Phenomena; Physiological Phenomena; Nervous System Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena; Geological Phenomena; Physical Phenomena; Environment; Ecological and Environmental Phenomena; Biological Phenomena; Environment and Public Health

Central Study Contacts

Ammar Ashraf Fathy

CONTACT

01028177808; ammarashraf154@gmail.com

Salah abdelazem Argoon

CONTACT

01019683366; argoons@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Ammar Ashraf

Study Record Dates

• First Submitted: October 3, 2023
• First Posted: October 10, 2023
• Study Start: December 1, 2023
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: October 10, 2023

Record last verified: 2023-10